Medical monitoring law is the tort doctrine that lets a person exposed to a hazardous substance recover the cost of diagnostic testing before any illness appears. Roughly a dozen states and the District of Columbia recognize some form of the claim, courts in about 28 states have rejected it, and the U.S. Supreme Court declined to adopt it under federal common law. Whether you can bring one depends almost entirely on where you live, what you were exposed to, and whether early screening would actually change your medical outcome.
Where the Claim Is Available
Jurisdiction is the single most important variable. Courts have landed in three camps. Some allow medical monitoring as a freestanding remedy when a plaintiff proves exposure and increased disease risk but has no present illness. Others reject the concept entirely, holding that without a current physical injury there is nothing to sue over. A smaller group falls in between, recognizing monitoring costs only as a category of damages attached to a traditional negligence claim rather than as an independent legal theory.
Among the states that permit some version of the claim, most limit it to toxic exposure or environmental contamination. Vermont is the only state that has enacted a statute specifically authorizing it. The others got there through court decisions, which means the rules can shift as new cases are decided.
The U.S. Supreme Court held in Metro-North Commuter Railroad Co. v. Buckley (1997) that federal common law does not support a standalone medical monitoring claim without present physical injury. That decision binds federal courts but does not prevent states from reaching different conclusions under their own tort law.
What You Have to Prove
Despite the jurisdictional split, courts that allow the claim have converged on a broadly similar test. The New Jersey Supreme Court set out an influential version in Ayers v. Township of Jackson (1987), and the California Supreme Court refined it in Potter v. Firestone Tire & Rubber Co. (1993). Most courts require you to show:
- Significant exposure to a hazardous substance at levels above normal background contamination.
- That the exposure resulted from the defendant’s negligent, reckless, or otherwise wrongful conduct.
- A meaningfully higher chance of developing a serious disease compared to the unexposed general population.
- That diagnostic procedures exist which can detect the disease at an early stage.
- That the recommended screening goes beyond what a doctor would normally prescribe for someone who was never exposed.
- That early detection through monitoring would actually improve health outcomes.
The last element is where many claims collapse. A court will not order a monitoring program just because exposure occurred. You have to show that catching the disease early leads to better treatment options, reduced mortality, or both. If the latent disease is equally lethal whether caught at stage one or stage three, the monitoring has no clinical benefit and the claim fails. The Potter court made this explicit by listing “the clinical value of early detection and diagnosis” as a distinct factor the jury must weigh.
Cause of Action or Just Damages
Courts that accept medical monitoring still disagree about what it actually is. Some treat it as its own cause of action, meaning you can file a lawsuit specifically seeking monitoring costs without needing to fit the claim into another legal category. Others view it as a form of damages available only after you prove an underlying tort such as negligence or nuisance. The West Virginia Supreme Court in Bower v. Westinghouse Electric Corp. (1999) took the latter view, holding that medical monitoring is a compensable item of damages under traditional tort theories rather than a new, independent tort.
The label matters at the margins. If monitoring is a standalone claim, a plaintiff whose exposure happened without clear negligence might still recover. If it is only a remedy, you must first prove someone was at fault. In practice, most successful cases involve clear negligence or recklessness by the defendant, so the distinction rarely changes the outcome. It can, however, affect how the lawsuit is framed, what defenses are available, and whether the claim survives a motion to dismiss.
Expert Testimony Is Not Optional
These claims live or die on expert testimony. You cannot simply assert that your exposure was dangerous and screening is needed. A qualified medical professional must testify that the specific monitoring program is reasonably necessary given the type, duration, and intensity of exposure. Federal courts and most state courts apply the standard from Daubert v. Merrell Dow Pharmaceuticals (1993), which requires expert testimony to be both relevant and reliable.
Under Federal Rule of Evidence 702, as amended, the party offering the expert must show the court that it is more likely than not that the opinion rests on sufficient facts, uses reliable methods, and applies those methods reliably to the case. Judges screen out speculation before it reaches a jury. In a medical monitoring case, the expert needs to explain the dose-response relationship for the specific substance, identify what diseases the exposure puts you at risk for, and describe which screening tests are medically accepted for early detection. A physician who testifies in general terms that an exposure “might cause problems,” without tying the opinion to peer-reviewed epidemiology, will likely be excluded.
Exposures That Typically Support a Claim
Medical monitoring claims cluster around a few recurring types of contamination.
PFAS Contamination
Per- and polyfluoroalkyl substances have become the dominant driver of new monitoring litigation. These chemicals, used in nonstick coatings, food packaging, and firefighting foams, accumulate in the body and have been linked to kidney cancer, thyroid disease, and other conditions. In 2024, the EPA finalized a national drinking water regulation setting maximum contaminant levels of 4.0 parts per trillion for both PFOA and PFOS, two of the most studied PFAS compounds.1US EPA. Per- and Polyfluoroalkyl Substances (PFAS) As of mid-2026, the EPA has proposed rescinding certain MCLs for other PFAS compounds and extending compliance deadlines for the PFOA and PFOS limits.2US EPA. Proposed PFAS Rescission Rule Communities near military bases, airports, and manufacturing plants where these chemicals contaminated groundwater have been at the center of large class actions seeking monitoring funds.
Asbestos and Industrial Chemicals
Asbestos litigation predates the modern medical monitoring framework and remains active. Workers who inhaled fibers from insulation, brake linings, or building materials face elevated risks of mesothelioma and asbestosis, diseases that can take 20 to 50 years to appear. Medical monitoring fits asbestos cases well because low-dose CT scans can detect lung abnormalities years before symptoms develop. Similar claims arise from exposure to benzene, vinyl chloride, and heavy metals like lead and cadmium in industrial settings.
Military and Government Site Contamination
One of the largest ongoing examples involves Camp Lejeune, where service members and their families were exposed to contaminated drinking water between 1953 and 1987. The Camp Lejeune Justice Act of 2022, enacted as part of the PACT Act, created a specific federal pathway for affected individuals to seek relief by filing administrative claims with the Department of the Navy.3U.S. Department of Veterans Affairs. Camp Lejeune Water Contamination Health Issues Communities near former nuclear production sites and Superfund cleanup areas face similar exposure profiles, often involving radioactive isotopes that warrant specialized thyroid and blood screenings.
How the Money Actually Reaches You
When a court awards medical monitoring, the remedy rarely arrives as a check in the mail. Courts generally prefer to establish a supervised fund that pays for approved diagnostic tests over time, rather than hand plaintiffs a lump sum they could spend on anything. The Massachusetts Supreme Judicial Court articulated this approach in Donovan v. Philip Morris USA, Inc., noting that unused monitoring funds may be returned to the defendant.
A court-appointed administrator typically manages the fund, processing claims from enrolled participants and paying healthcare providers directly. The court keeps jurisdiction over the fund for the entire monitoring period, which can stretch for decades depending on the latency of the disease. If a new, more effective screening test becomes available, the court can modify the program to incorporate it. Whatever is left at the end usually reverts to the defendant.
Lump-sum awards do occur, more often in individual lawsuits than in class actions. The plaintiff receives the estimated present value of all future monitoring costs and manages the money independently. That gives you more control, but no guarantee the money will actually be spent on testing.
Filing Deadlines and the Discovery Rule
Statutes of limitations pose a unique problem here because the harm you are trying to prevent may not appear for years or decades. Most jurisdictions apply some version of the discovery rule, which delays the filing clock until you knew or reasonably should have known about the exposure and its connection to a potential health risk. The triggering event is not when you were physically exposed, but when you learned the exposure was hazardous.
Federal law reinforces this for hazardous substance cases. Under the Comprehensive Environmental Response, Compensation, and Liability Act, the statute of limitations does not begin until the plaintiff knew or reasonably should have known that the personal injury was caused by the hazardous substance in question. This federally required commencement date preempts shorter state filing deadlines in qualifying cases.
The practical challenge is proving when you became aware. If your local water utility issued a contamination notice in 2022 and you did not file until 2026, a court might find the clock started running in 2022 regardless of when you actually read the notice. Keep contamination reports, news clippings, and any official notifications. That paper trail can be the difference between a viable claim and a time-barred one.
Will You Owe Tax on What You Receive
Whether a medical monitoring award is taxable depends on how it is characterized. Under the Internal Revenue Code, damages received on account of personal physical injuries or physical sickness are excluded from gross income.4Office of the Law Revision Counsel. 26 USC 104 – Compensation for Injuries or Sickness Medical monitoring sits in a gray zone because you typically have not yet developed a physical illness. Courts and the IRS have not uniformly agreed that pre-symptomatic monitoring payments qualify for the exclusion.
If the funds flow through a qualified settlement fund, the fund itself is taxed on investment income it earns but not on the principal settlement amount transferred into it. The fund administrator files an annual tax return and must issue 1099 forms to claimants for any distributions that count as reportable gross income. If your monitoring payments are treated as compensatory damages for physical injury, they should be tax-free to you. If they are treated as general damages unrelated to a present physical injury, they may be taxable. Talk to a tax professional before you assume either answer, because the result turns on facts specific to your settlement and your state’s classification of the claim.